Expectant management of patent ductus arteriosus for preterm infants: A meta-analysis of randomized controlled trials

Am Heart J. 2023 Dec:266:179-183. doi: 10.1016/j.ahj.2023.07.007. Epub 2023 Aug 9.

Abstract

We conducted this meta-analysis to compare expectant management of patent ductus arteriosus (PDA) with active treatment for PDA closure in preterm infants. Data from 7 randomized controlled trials (RCTs) showed that all-cause mortality and other clinical adverse outcomes did not differ between expectant management of PDA and active treatment. Future large-scale and double-blinded RCTs with a consistent definition for hemodynamically significant PDA, and focusing on clearly delineated high-risk subgroups or later selective treatment are needed to further evaluate the role of expectant management.

Publication types

  • Meta-Analysis

MeSH terms

  • Ductus Arteriosus, Patent* / therapy
  • Humans
  • Ibuprofen / adverse effects
  • Indomethacin / therapeutic use
  • Infant, Low Birth Weight
  • Infant, Newborn
  • Infant, Premature
  • Randomized Controlled Trials as Topic
  • Watchful Waiting

Substances

  • Indomethacin
  • Ibuprofen